Mr. Kevin Rakin has more than 20 years of experience in the biotechnology industry and was most recently the President of Regenerative Medicine at Shire plc, a leading specialty biopharmaceutical company (Shire). Prior to joining Shire, Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from 2007 until its acquisition by Shire for $750 million in June 2011. Before this, he served at the interim CEO of ABH and executive-in-residence at Canaan Partners. Previously, he was a co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, a publicly-held pharmacogenomics company, until its merger with Clinical Data in October 2005. Prior to that, he was Genaissance’s President and Chief Financial Officer and was responsible for completing private and public financings in excess of $150 million.

Mr. Kevin Rakin has more than 20 years of experience in the biotechnology industry and was most recently the President of Regenerative Medicine at Shire plc, a leading specialty biopharmaceutical company (Shire). Prior to joining Shire, Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from 2007 until its acquisition by Shire for $750 million in June 2011. Before this, he served at the interim CEO of ABH and executive-in-residence at Canaan Partners. Previously, he was a co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, a publicly-held pharmacogenomics company, until its merger with Clinical Data in October 2005. Prior to that, he was Genaissance’s President and Chief Financial Officer and was responsible for completing private and public financings in excess of $150 million.